Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biocept, Inc. (BIOC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0500+0.0549 (+5.52%)
At close: 04:00PM EDT
1.0100 -0.04 (-3.81%)
After hours: 06:43PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close0.9951
Open1.0000
Bid1.0100 x 1200
Ask1.0700 x 4000
Day's Range0.9900 - 1.0700
52 Week Range0.8400 - 4.4400
Volume136,810
Avg. Volume104,330
Market Cap17.769M
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-0.5240
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BIOC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biocept, Inc.
    Analyst Report: Guardant Health, Inc.Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Business Wire

    Biocept Appoints RSM as Independent Auditor

    SAN DIEGO, June 27, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP ("RSM") as its independent registered public accounting firm effective June 24, 2022. RSM was recently ranked the fifth largest accounting, tax and consulting services firm in the U.S. for the 16th straight year by Accounting Today.

  • GlobeNewswire

    Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

    Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enrolling in Plus Therapeutics’ ReSPECT-LM clinical trial AUSTIN, Texas and SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiot

  • Business Wire

    Biocept to Hold Business Strategy Conference Call Today

    SAN DIEGO, June 07, 2022--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.

Advertisement
Advertisement